Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis

Exclusion Criteria

• •Sex and Reproductive Status
• •1. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 12 weeks after the last dose of study drug.
• •2. WOCBP using a prohibited contraceptive method.
• •3. Women who are pregnant or breastfeeding.
• •4. Women with a positive pregnancy test on enrollment or before administration of tofacitinib.
• •5. Sexually active fertile men not using effective birth control if their partners are WOCBP.
• •Target Disease Exceptions
• •1. Patients with current alopecia totalis/universalis (i.e. 100% scalp or 100% scalp and body loss, respectively) may be enrolled.
• •2. Patients with a history of or active skin disease on the scalp such as psoriasis or seborrheic dermatitis.
• •3. Patients in whom the diagnosis of alopecia areata is in question or in whom the pattern of hair loss is such that quantification of hair loss and assessment of regrowth is difficult. E.g patients with diffuse alopecia areata. This assessment is at the investigator's discretion.
• •4. Patients with active medical conditions or malignancies (except adequately treated basal or squamous cell carcinoma) that in the opinion of the investigator would increase the risks associated with study participation, including patients with a history of recurrent infections.
• •5. Patients with hemoglobin levels \<9 g/dL, lymphocyte count \<500 cells/mm3, absolute neutrophil count (ANC) \<1000 cells/mm3, at baseline.
• •6. Patients known to be HIV or hepatitis B or C positive.
• •7. Patients with history or evidence of moderate or severe hepatic and/or renal impairment.
• •8. Patients with history of immunosuppression or history of recurrent serious infections.
• •Coexisting disease or concurrent medications
• •1. Patients taking potent inhibitors of CYP3A4 (e.g.ketoconazole).
• •2. Patients receiving one or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole).
• •3. Patients known to be HIV or hepatitis B or C positive.
• •4. Patients with evidence of infection or active/untreated skin cancer.
• •5. Patients who have been treated with intralesional steroids, systemic steroids, anthralin, squaric acid, diphenylcyclopropenone (DPCP), protopic, minoxidil or other medication which in the opinion of the investigator may affect hair regrowth within one month of the baseline visit.
• •6. Patients who are impaired, incapacitated, or incapable of completing study-related assessments.
• •7. Patients with current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, which, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study.
• •8. Female patients who have had a breast cancer screening that is suspicious for malignancy and in whom the possibility of malignancy cannot be reasonably excluded by additional clinical, laboratory, or other diagnostic evaluations.
• •9. Patients with a history of cancer in the last 5 years, other than non-melanoma skin cell cancers cured by local resection or carcinoma in situ. Existing non-melanoma skin cell cancers should be removed, the lesion site healed, and residual cancer ruled out before administration of the study drug.
• •10. Patients who currently abuse drugs or alcohol.
• •11. Patients with evidence (as assessed by the investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of human immunodeficiency virus (HIV) detected during screening.
• •12. Patients with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months before the informed consent document was signed.
• •13. Patients who have received any live vaccines within 3 months of the anticipated first dose of study medication. Subjects may not receive live vaccine concurrently with tofacitinib.
• •14. Patients with a history or symptoms suggestive of gastrointestinal perforation or disorders that might increase the risk of GI perforation such as gastric ulcers or diverticulitis.
• •15. Patients who take NSAIDs at high dose or on a frequent basis, which in the investigator's opinion might increase the risks of gastrointestinal perforation.
• •16. Patients with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, or bronchiectasis).
• •17. Patients at risk for tuberculosis (TB). Specifically excluded from this study will be subjects with a history of active TB within the last 3 years, even if it was treated; a history of active TB greater than 3 years ago, unless there is documentation that the prior anti-TB treatment was appropriate in duration and type; current clinical, radiographic, or laboratory evidence of active TB; and latent TB that was not successfully treated (4 weeks).